LONDON, July 13, 2022 (GLOBE NEWSWIRE) — The “Type 2 Diabetes (Metabolic Disorder) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update” report offered by Globaldata provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.
Type 2 Diabetes Pipeline Drugs Market – Competitive Landscape
- Eli Lilly and Co
- Novo Nordisk AS
- Merck & Co Inc
- Tonghua Dongbao Pharmaceutical Co Ltd
- Chong Kun Dang Pharmaceutical Corp
- Sihuan Pharmaceutical Holdings Group Ltd
Number of Type 2 Diabetes Pipeline Products, by Leading Companies
To know more about leading type 2 diabetes pipeline product companies, download a sample report
Eli Lilly and Co
Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
Novo Nordisk AS
Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company that discovers, develops, and manufactures innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. With subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia, the company markets its products in several countries. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Merck & Co Inc
Merck & Co Inc (Merck) is a biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
Other Leading Companies in the Type 2 Diabetes Pipeline Drugs Market
- AstraZeneca Plc
- Diasome Pharmaceuticals Inc
- Intarcia Therapeutics Inc
- Thermalin Inc
- Adocia SAS
- Hanmi Pharmaceuticals Co Ltd
- Pfizer Inc
- Akston Biosciences Corp
- Algiax Pharmaceuticals GmbH
- Biocon Ltd
- Others
Type 2 Diabetes Therapeutics Assessment by Targets
- Glucagon Like Peptide 1 Receptor
- Insulin Receptor
- Dipeptidyl Peptidase 4
- Sodium/Glucose Cotransporter 2
- Adenosine Monophosphate Activated Protein Kinase
- Others
Number of Type 2 Diabetes Pipeline Products, by Targets
For more target insights on type 2 diabetes pipeline products market, download a sample report
Type 2 Diabetes Therapeutics Assessment by MoA
- Glucagon Like Peptide 1 Receptor Agonist
- Insulin Receptor Agonist
- Dipeptidyl Peptidase 4 Inhibitor
- Sodium/Glucose Cotransporter 2 Inhibitor
- Adenosine Monophosphate Activated Protein Kinase Activator
- Others
Number of Type 2 Diabetes Pipeline Products, by MoA
For more MoA insights on type 2 diabetes pipeline products market, download a sample report
Type 2 Diabetes Therapeutics Assessment by RoA
- Oral
- Subcutaneous
- Parenteral
- Intravenous
- Transdermal
- Buccal
- Inhalational
- Sublingual
- Intraarticular
- Intracardiac
- Others
Number of Type 2 Diabetes Pipeline Products, by RoA
For more RoA insights on type 2 diabetes pipeline products market, download a sample report
Type 2 Diabetes Therapeutics Assessment by Molecule Type
- Small Molecule
- Recombinant Peptide
- Synthetic Peptide
- Peptide
- Fusion Protein
- Recombinant Protein
- Biologic
- Monoclonal Antibody
- Cell Therapy
- Gene Therapy
- Others
Number of Type 2 Diabetes Pipeline Products, by Molecule Type
For more small molecule insights on type 2 diabetes pipeline products market, download a sample report
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Related Reports
- Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
- Metastatic Melanoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update – Click here
- Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
- Hypoglycemia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update – Click here
- Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical Trial Anaylsis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update – Click here
Type 2 Diabetes Pipeline Drugs Market Report Overview
| Key Targets | Glucagon Like Peptide 1 Receptor, Insulin Receptor, Dipeptidyl Peptidase 4, Sodium/Glucose Cotransporter 2, Adenosine Monophosphate Activated Protein Kinase, and Others |
| Key MoA | Glucagon Like Peptide 1 Receptor Agonist, Insulin Receptor Agonist, Dipeptidyl Peptidase 4 Inhibitor, Sodium/Glucose Cotransporter 2 Inhibitor, Adenosine Monophosphate Activated Protein Kinase Activator, Others |
| Key RoA | Oral, Subcutaneous, Parenteral, Intravenous, Transdermal, Buccal, Inhalational, Sublingual, Intraarticular, Intracardiac, and Others |
| Key Molecule Type | Small Molecule, Recombinant Peptide, Synthetic Peptide, Peptide, Fusion Protein, Recombinant Protein, Biologic, Monoclonal Antibody, Cell Therapy, Gene Therapy, and Others |
| Leading Companies | Eli Lilly and Co, Novo Nordisk AS, Merck & Co Inc, Tonghua Dongbao Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Sihuan Pharmaceutical Holdings Group Ltd, AstraZeneca Plc, Diasome Pharmaceuticals Inc, Intarcia Therapeutics Inc, Thermalin Inc, Adocia SAS, Hanmi Pharmaceuticals Co Ltd, Pfizer Inc, Akston Biosciences Corp, Algiax Pharmaceuticals GmbH, Biocon Ltd, and Others |
FAQs
What are the key targets in the type 2 diabetes pipeline drugs market?
The key targets in the type 2 diabetes pipeline products market are glucagon like peptide 1 receptor, insulin receptor, dipeptidyl peptidase 4, sodium/glucose cotransporter 2, adenosine monophosphate activated protein kinase, and others.
What are the key MoA in the type 2 diabetes pipeline drugs market?
The key mechanisms of action in the type 2 diabetes pipeline products market are glucagon like peptide 1 receptor agonist, insulin receptor agonist, dipeptidyl peptidase 4 inhibitor, sodium/glucose cotransporter 2 inhibitor, adenosine monophosphate activated protein kinase activator, others.
What are the key RoA in the type 2 diabetes pipeline drugs market?
The key routes of administration in the type 2 diabetes pipeline products market are oral, subcutaneous, parenteral, intravenous, transdermal, buccal, inhalational, sublingual, intraarticular, intracardiac, and others.
What are the key molecule types in the type 2 diabetes pipeline drugs market?
The key molecule types in the type 2 diabetes pipeline products market are small molecule, recombinant peptide, synthetic peptide, peptide, fusion protein, recombinant protein, biologic, monoclonal antibody, cell therapy, gene therapy, and others.
What are the key companies in the type 2 diabetes pipeline drugs market?
The major companies in the type 2 diabetes pipeline products market are Eli Lilly and Co, Novo Nordisk AS, Merck & Co Inc, Tonghua Dongbao Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Sihuan Pharmaceutical Holdings Group Ltd, AstraZeneca Plc, Diasome Pharmaceuticals Inc, Intarcia Therapeutics Inc, Thermalin Inc, Adocia SAS, Hanmi Pharmaceuticals Co Ltd, Pfizer Inc, Akston Biosciences Corp, Algiax Pharmaceuticals GmbH, Biocon Ltd, and others.
Table of Contents
Introduction
- Type 2 Diabetes – Overview
- Type 2 Diabetes – Therapeutics Development
- Type 2 Diabetes – Therapeutics Assessment
- Type 2 Diabetes – Companies Involved in Therapeutics Development
- Type 2 Diabetes – Drug Profiles
- Type 2 Diabetes – Dormant Projects
- Type 2 Diabetes – Discontinued Products
- Type 2 Diabetes – Product Development Milestones
- Appendix
About us
GlobalData is a leading provider of data, analytics, and insights on the world’s largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData’s mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
